Detailed Information

Cited 0 time in webofscience Cited 0 time in scopus
Metadata Downloads

Phase II study to investigate the efficacy of trastuzumab biosimilar (Herzuma (R)) plus treatment of physician's choice (TPC) in patients with heavily pretreated HER-2+metastatic breast cancer (KCSG BR 18-14/KM10B)open access

Authors
Sim, Sung HoonKim, Jeong EunKim, Min HwanPark, Yeon HeeKim, Jee HyunSuh, Koung JinKoh, Su-JinPark, Kyong HwaKang, Myoung JooAhn, Mi SunLee, Kyoung EunKim, Hee-JunAhn, Hee KyungKim, Han JoPark, Keon UkByun, Jae HoPark, Jin HyunLee, Gyeong-WonLee, Keun SeokSohn, JoohyukJung, Kyung HaePark, In Hae
Issue Date
Oct-2022
Publisher
Churchill Livingstone
Keywords
HER2 positive; Metastatic breast cancer; Trastuzumab biosimilar; Clinical trial; ctDNA
Citation
Breast, v.65, pp.172 - 178
Indexed
SCIE
SCOPUS
Journal Title
Breast
Volume
65
Start Page
172
End Page
178
URI
https://scholarworks.korea.ac.kr/kumedicine/handle/2021.sw.kumedicine/61503
DOI
10.1016/j.breast.2022.08.002
ISSN
0960-9776
Abstract
We investigated the efficacy and safety of a trastuzumab biosimilar, Herzuma (R), in combination with treatment of physician's choice (TPC) in patients with HER2+ metastatic breast cancer (MBC) who had failed at least two HER2 directed chemotherapies.
Files in This Item
There are no files associated with this item.
Appears in
Collections
2. Clinical Science > Department of Medical Oncology and Hematology > 1. Journal Articles

qrcode

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.

Related Researcher

Researcher Park, In Hae photo

Park, In Hae
Guro Hospital (Department of Medical Oncology and Hematology, Guro Hospital)
Read more

Altmetrics

Total Views & Downloads

BROWSE